Degron Therapeutics
Develops molecular glue degrader medicines targeting previously undruggable proteins
$40MSeries A+
Role not disclosedGX
GF Xinde
Activity from announced rounds
Activity in this selectionBiotech
GF Xinde is the investment-manager brand named in Degron and DeepCtrls financing histories.
Recorded funding activity
Degron develops molecular-glue medicines for previously difficult protein targets. DeepCtrls coordinates power, cooling and computing through physical AI. The recorded companies address different biological and industrial operating problems.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $40M 1 disclosed · full round size, not this investor’s share